Phenotyping tricuspid regurgitation: time to integrate left-sided heart failure

View at publisher Summarise with VIRAT
Authors: Christian Basile, Carlo Lombardi, Riccardo Maria Inciardi
Cited by: 0
References: 9

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This editorial refers to ‘Left-sided heart failure determines outcomes in patients with severe tricuspid regurgitation undergoing percutaneous repair, by S. Rosch et al., https://doi.org/10.1093/ejhf/xuag078 The trajectory of tricuspid regurgitation (TR) management has undergone a profound transformation over the past decade, evolving from a state of clinical neglect, in which the valve was famously dubbed ‘forgotten’, to a frontier of structural heart intervention.1 Historically, the tricuspid valve was viewed merely as a passive bystander to left-sided heart disease, a marker of late-stage pathology rather than a therapeutic target in its own right. Surgical dogma held that addressing mitral or aortic pathology would lead to spontaneous resolution of functional TR, a hypothesis that has been systematically dismantled by long-term outcome data showing that TR persists and progresses in a significant proportion of patients following left-sided surgery.2 Transcatheter edge-to-edge repair (TEER) has provided a feasible, less invasive option for patients deemed at prohibitive surgical risk.3,4 The initial wave of enthusiasm, buoyed by high procedural success rates and favourable safety profiles observed in early feasibility studies as well as the success of the TRILUMINATE randomized controlled trial (RCT), has recently encountered the friction of real-world complexity. While quality-of-life improvements were shown in the TRILUMINATE non-sham-controlled RCT, a mortality benefit relative to medical therapy has remained elusive in RCTs. In fact, in the TRILUMINATE and Tri.FR RCTs, only 9% and 3% of patients experienced mortality by any cause after 1 year, respectively, displaying a significant discordance with real-world data showing 11–19% of patients dying within one year after TR TEER, probably reflecting a highly selected population compared with the real world.3,5

Fields of Study & Subjects

Cardiac Valve Diseases and Treatments Cardiac Structural Anomalies and Repair Cardiac Arrhythmias and Treatments

Publication details

Journal / source
European Journal of Heart Failure
Publication date
26 March 2026
Language
EN